These innovative compounds represent a significant advancement in the management of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in reducing blood glucose https://jakubbiat931987.is-blog.com/45965819/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide